Drug intelligence / Profile preview

silodosin + tadalafil

Development stage
Unknown
Lead developer
Kissei Pharmaceutical
Modality
Small Molecules
Administration
Oral
01

Overview

Silodosin + tadalafil is a fixed-dose combination of two small molecule drugs used primarily for the treatment of lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH), particularly in men who may also have erectile dysfunction. Silodosin is a highly selective alpha-1A-adrenoceptor antagonist that relaxes smooth muscle in the prostate and bladder neck, improving urine flow and reducing BPH symptoms. Tadalafil is a phosphodiesterase type 5 (PDE5) inhibitor that increases cyclic guanosine monophosphate (cGMP) levels, leading to smooth muscle relaxation in the lower urinary tract and corpus cavernosum, thereby improving both LUTS and erectile function. Clinical studies demonstrate that this combination provides greater improvement in urinary flow rate, symptom scores, and erectile function than either drug alone[1][3][9]. The combination has also been studied as medical expulsive therapy for distal ureteric stones[4].

Brand names
Thrupass
Other names
Silodosin/Tadalafil FDCThrupass combination
02

Targets

PDE5 (Phosphodiesterase 5A)ADRA1A (α1A)

Beyond the preview

Go deeper on silodosin + tadalafil.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on silodosin + tadalafil.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call